Foghorn Therapeutics

Cancer Drug Discovery, Protein Degradation

Also Clin1 AML; FHD-609 Clin1 synovial sarcoma; 9 undisclosed programs Clin0 oncology, undisclosed; undisclosed programs RD undisclosed

Foghorn Therapeutics’ Gene Traffic Control platform is designed to target and modulate the chromatin regulatory system. Components of the chromatin regulatory system are synthesized and used for proprietary assays to guide the discovery and optimization of drug targets. High throughput screening of candidate compounds is then used to discover drugs that modulate the chromatin regulatory system. Foghorn currently has multiple therapeutics targeting cancer in Phase 1 clinical trials in addition to therapeutics targeting transcription factors and synthetic lethal targets, among others, in discovery stages. Phase 1 trials are currently enrolling for uveal melanoma, synovial sarcoma, acute myeloid leukemia, and myelodysplastic syndrome.